File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Preoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantation

TitlePreoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantation
Authors
Issue Date2001
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jcrs
Citation
Journal Of Cataract And Refractive Surgery, 2001, v. 27 n. 11, p. 1792-1795 How to Cite?
AbstractPurpose: To evaluate the efficacy of latanoprost given 2 hours preoperatively to prevent ocular hypertension in the early period after phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation. Setting: Departments of Ophthalmology, United Christian Hospital and Prince of Wales Hospital, Hong Kong, China. Methods: Sixty-four eyes of 64 patients with uncomplicated cataract having phacoemulsification with PC IOL implantation were included in this prospective randomized double-masked clinical trial. The eyes were randomly assigned to 1 of 2 groups: application of latanoprost 0.005% 2 hours before surgery or no latanoprost (control). Intraocular pressure (IOP) was measured 3 and 24 hours postoperatively. The anterior chamber was examined for the level of cells and flare using a slitlamp biomicroscope. The level of significance was 5%. Results: The decrease in the mean IOP was not statistically significantly different between eyes receiving latanoprost 2 hours preoperatively and control eyes 3 hours (P = .843) and 24 hours (P = .721) postoperatively. Conclusion: A single application of latanoprost given 2 hours before phacoemulsification and PC IOL implantation did not produce a statistically significant IOP-lowering effect when compared with a control group in the first 24 hours after surgery. © 2001 ASCRS and ESCRS.
Persistent Identifierhttp://hdl.handle.net/10722/176375
ISSN
2015 Impact Factor: 3.02
2015 SCImago Journal Rankings: 1.946
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, JSMen_US
dc.contributor.authorLoo, Aen_US
dc.contributor.authorTham, CCYen_US
dc.contributor.authorHo, SYen_US
dc.contributor.authorLam, DSCen_US
dc.date.accessioned2012-11-26T09:10:53Z-
dc.date.available2012-11-26T09:10:53Z-
dc.date.issued2001en_US
dc.identifier.citationJournal Of Cataract And Refractive Surgery, 2001, v. 27 n. 11, p. 1792-1795en_US
dc.identifier.issn0886-3350en_US
dc.identifier.urihttp://hdl.handle.net/10722/176375-
dc.description.abstractPurpose: To evaluate the efficacy of latanoprost given 2 hours preoperatively to prevent ocular hypertension in the early period after phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation. Setting: Departments of Ophthalmology, United Christian Hospital and Prince of Wales Hospital, Hong Kong, China. Methods: Sixty-four eyes of 64 patients with uncomplicated cataract having phacoemulsification with PC IOL implantation were included in this prospective randomized double-masked clinical trial. The eyes were randomly assigned to 1 of 2 groups: application of latanoprost 0.005% 2 hours before surgery or no latanoprost (control). Intraocular pressure (IOP) was measured 3 and 24 hours postoperatively. The anterior chamber was examined for the level of cells and flare using a slitlamp biomicroscope. The level of significance was 5%. Results: The decrease in the mean IOP was not statistically significantly different between eyes receiving latanoprost 2 hours preoperatively and control eyes 3 hours (P = .843) and 24 hours (P = .721) postoperatively. Conclusion: A single application of latanoprost given 2 hours before phacoemulsification and PC IOL implantation did not produce a statistically significant IOP-lowering effect when compared with a control group in the first 24 hours after surgery. © 2001 ASCRS and ESCRS.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jcrsen_US
dc.relation.ispartofJournal of Cataract and Refractive Surgeryen_US
dc.subject.meshAgeden_US
dc.subject.meshAntihypertensive Agents - Therapeutic Useen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIntraocular Pressure - Drug Effectsen_US
dc.subject.meshLens Implantation, Intraocular - Adverse Effectsen_US
dc.subject.meshMaleen_US
dc.subject.meshOcular Hypertension - Etiology - Prevention & Controlen_US
dc.subject.meshPhacoemulsification - Adverse Effectsen_US
dc.subject.meshPreoperative Careen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshProstaglandins F, Synthetic - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.titlePreoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantationen_US
dc.typeArticleen_US
dc.identifier.emailLai, JSM: laism@hku.hken_US
dc.identifier.authorityLai, JSM=rp00295en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0886-3350(01)00902-6en_US
dc.identifier.pmid11709253-
dc.identifier.scopuseid_2-s2.0-0035173865en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035173865&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue11en_US
dc.identifier.spage1792en_US
dc.identifier.epage1795en_US
dc.identifier.isiWOS:000172079600022-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, JSM=7401939748en_US
dc.identifier.scopusauthoridLoo, A=7003815216en_US
dc.identifier.scopusauthoridTham, CCY=7006081241en_US
dc.identifier.scopusauthoridHo, SY=36839067000en_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats